株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

中国の遺伝子組み換えフォリトロピンベータ市場の分析

Investigation Report on China's Recombinant Follitropin Beta Market, 2019-2023

発行 China Research and Intelligence 商品コード 907271
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.74円で換算しております。
Back to Top
中国の遺伝子組み換えフォリトロピンベータ市場の分析 Investigation Report on China's Recombinant Follitropin Beta Market, 2019-2023
出版日: 2019年08月20日 ページ情報: 英文 30 Pages
概要

当レポートでは、中国国内の遺伝子組み換えフォリトロピンベータ市場について分析し、製品の概略・効能や許認可状況、全体的な市場規模の動向見通し (過去・今後5年間分)、市場価格の推移と見通し、主要企業のプロファイルと市場シェア、といった情報を取りまとめてお届けいたします。

第1章 遺伝子組み換えフォリトロピンベータの関連概念

  • 遺伝子組み換えフォリトロピンベータの適応症
  • 中国の遺伝子組み換えフォリトロピンベータ市場の発展
  • 中国国内の遺伝子組み換えフォリトロピンベータの関連特許と政府承認動向

第2章 中国国内の遺伝子組み換えフォリトロピンベータの売上高

  • 遺伝子組み換えフォリトロピンベータの販売額
    • 全体的な販売額
    • 地域別の販売額
  • 遺伝子組み換えフォリトロピンベータの販売量
    • 全体的な販売量
    • 地域別の販売量
  • 遺伝子組み換えフォリトロピンベータの販売額:剤型別 (過去5年間分)

第3章 遺伝子組み換えフォリトロピンベータの主要メーカーの分析

  • 主要メーカーの市場シェアの分析
    • 金額ベース
    • 数量ベース
  • Organon
    • 企業プロファイル
    • 中国国内での遺伝子組み換えフォリトロピンベータの売上高

第4章 遺伝子組み換えフォリトロピンベータの国内価格

  • Organon (Puregon)
  • 遺伝子組み換えフォリトロピンベータの価格動向

第5章 中国の遺伝子組み換えフォリトロピンベータ市場の将来展望

  • 市場への影響要因
    • 市場促進要因と市場機会
    • 脅威と課題
  • 市場規模の予測 (今後5年間分)
  • 市場動向の予測 (今後5年間分)
目次
Product Code: 1908399

Description

In China, the number of infertile couples is increasing. According to Chinese media, in 2018, more than 40 million people in China were infertile, with the incidence of infertility in couples of childbearing age increasing from 3% 20 years ago to 15% in recent years. According to the Global Burden of Disease, in 2017, the incidence of infertility was 2,705.66/100,000 in Chinese women and 879.32/100,000 in Chinese men. The common causes of female infertility include ovulation disorders, fallopian tube damages and endometriosis; the major causes of male infertility include varicoceles, infections, ejaculation disorders and anti-sperm antibodies.

The increasing incidence of infertility in China is attributable to the endocrine disorders caused by worsening environmental pollution, increasing life pressures and unhealthy lifestyle, the increase in the average childbearing age of women, and the damages to female fertility caused by induced abortion.

Infertility is mainly treated by drug, surgery and assisted reproductive technology (ART). The drugs are ovulation stimulants that apply to the couples who have no organic disorders. Surgeries apply to organic disorders such as varicoceles in men and blocked fallopian tubes and intrauterine adhesion in women.

If drugs or surgeries do not work or if couples have other indications, ART will be applied. About 20% infertility patients are treated by ART. ART procedures mainly include artificial insemination (AI) and in vitro fertilization and embryo transfer (IVF-ET, or test-tube baby) and their derivative technologies. They bring higher pregnancy rate than drugs and surgeries. As the success rate of AI is lower, some patients directly choose IVF-ET. And some patients turn to IVF-ET after repeated AI failures. At the end of 2018, more than 450 medical institutions were qualified to implement ART, of which 350 could implement IVF-ET and more than 40 could provide pre-implantation genetic diagnosis; the number of ART practitioners reached 10,000; the clinical pregnancy rate of ART in China was 40% and the live birth rate was 30% to 35%. China have over 200,000 newborn test-tube babies every year, ranking the first in the world.

In 2006, the Recombinant Follitropin Beta injection by Merck Sharp & Dohme became the first Recombinant Follitropin Beta product approved to be sold in China. In 2011, Recombinant Follitropin Beta (trade name: Puregon) by Organon (now affiliated to Merck Sharp & Dohme) was approved to be sold in China. And all the Recombinant Follitropin Beta products on the Chinese market are the products of Organon. The sales value of Recombinant Follitropin Beta kept rising after the drug entered China. It reached about CNY 126 million in 2017.

In China, Recombinant Follitropin Beta is used to treat anovulation (including polycystic ovary disease, PCOD) that cannot be cured by clomiphene citrate. It is also used in ART procedures such as IVF-ET, gamete intrafallopian transfer (GIFT) and Intracytoplasmic sperm injection (ICSI) for controlled ovarian hyperstimulation and follicular development.

As the incidence of infertility increases, the demand for Recombinant Follitropin Beta in China will keep growing. From 2019 to 2023, China's Recombinant Follitropin Beta market will continue to expand. In the next few years, Recombinant Follitropin Beta products by enterprises other than Organon will possibly be launched in China.

Topics covered:

  • Incidence of infertility in China
  • Status of China's Recombinant Follitropin Beta market
  • Prices of Recombinant Follitropin Beta in China
  • Major factors influencing development of China's Recombinant Follitropin Beta market
  • Prospect of China's Recombinant Follitropin Beta market from 2019 to 2023

Table of Contents

1 Relevant Concepts of Recombinant Follitropin Beta

  • 1.1 Indications for Recombinant Follitropin Beta
  • 1.2 Development of Recombinant Follitropin Beta in China
  • 1.3 Patents and Government Approval on Recombinant Follitropin Beta in China

2 Sales of Recombinant Follitropin Beta in China, 2013-2017

  • 2.1 Sales Value of Recombinant Follitropin Beta
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Recombinant Follitropin Beta
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Recombinant Follitropin Beta by Dosage Form in China, 2013-2017

3 Analysis on Major Manufacturers of Recombinant Follitropin Beta in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Manufacturers of Recombinant Follitropin Beta
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 Organon
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Recombinant Follitropin Beta by Organon in China

4 Prices of Recombinant Follitropin Beta in China, 2017-2018

  • 4.1 Organon (Puregon)
  • 4.2 Price Trend of Recombinant Follitropin Beta

5 Prospect of China's Recombinant Follitropin Beta Market, 2019-2023

  • 5.1 Factors Influencing Development of China's Recombinant Follitropin Beta Market
    • 5.1.1 Driving Forces and Market Opportunities
    • 5.1.2 Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

Selected Charts

  • Chart Patents on Recombinant Follitropin Beta in China
  • Chart Government Approval on Recombinant Follitropin Beta in China
  • Chart Sales of Recombinant Follitropin Beta in China, 2013-2017
  • Chart Sales Value of Recombinant Follitropin Beta in Parts of China, 2013-2017
  • Chart Sales Volume of Recombinant Follitropin Beta in China, 2013-2017
  • Chart Sales Volume of Recombinant Follitropin Beta in Parts of China, 2013-2017
  • Chart Sales Value of Recombinant Follitropin Beta Injections in China, 2013-2017
  • Chart Sales Volume of Recombinant Follitropin Beta Injections in China, 2013-2017
  • Chart Sales Value of Recombinant Follitropin Beta by Organon in China, 2013-2017
  • Chart Sales Volume of Recombinant Follitropin Beta by Organon in China, 2013-2017
  • Chart Prices of Recombinant Follitropin Beta by Organon in Parts of China, 2017-2018
  • Chart Forecast on Sales Value of Recombinant Follitropin Beta in China, 2019-2023
Back to Top